Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 9.96M
Average 6.11M
Dividends
Intellia Therapeutics, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Intellia Therapeutics, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | 0.00% | $0.00 | 0.00% | 0.00% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | 0.00% | $0.00 | 0.00% | 0.00% |
uniQure N.V. NASDAQ:QURE | $1.67B | 0.00% | $0.00 | 0.00% | 0.00% |
Precigen, Inc. NASDAQ:PGEN | $1.63B | 0.00% | $0.00 | 0.00% | 0.10% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | 0.00% | $0.00 | 0.00% | 2.32% |
Sana Biotechnology, Inc. NASDAQ:SANA | $605.26M | 0.00% | $0.00 | 0.00% | 0.00% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | 0.00% | $0.00 | 0.00% | 0.09% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | 0.00% | $0.00 | 0.00% | 0.00% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about NTLA's dividend, answered from reported figures.
Does NTLA stock pay dividends?
Intellia Therapeutics, Inc. (NTLA) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is NTLA's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.